InvestorsHub Logo
Followers 91
Posts 11356
Boards Moderated 0
Alias Born 06/06/2014

Re: TempePhil post# 328019

Saturday, 08/28/2021 7:10:37 PM

Saturday, August 28, 2021 7:10:37 PM

Post# of 462908
That's a good article, and thanks also for your views.

The problems with the blot and staining images seem to stem from Wang's lab, since the author amazingly found other problematic Wang lab papers (pretty clearly not Cassava related). Wang's lab is either careless or cutting corners. Or perhaps worse: doctoring results (and doing it very sloppily). The latter is tough to believe and quite rare in established university labs.

So while Dr Burns (Cassava scientist) is co-author with Wang, Wang may be the problem. This of course still means the blot studies would be unreliable, just that it might be Wang's sole doing (i.e., no Cassava involvement). Separate from the responsibility issue, I think the blot "splicing" etc might have legitimate explanations, but the apparent duplicates will be much harder to explain away.

And of course the table/chart mismatch from the efficacy trial is all Cassava. As their contractor Quanterix made embarrassingly clear.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News